Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy

International Journal of Urology

Volumn 20, Issue 4, 2013, Pages 413-419

  Gandaglia, Giorgio ^a   Albersen, Maarten ^b   Suardi, Nazareno ^a   Gallina, Andrea ^a   Abdollah, Firas ^a   Castiglione, Fabio ^a   Capitanio, Umberto ^a   Salonia, Andrea ^a   Rigatti, Patrizio ^a   Hedlund, Petter ^a   Montorsi, Francesco ^a   Briganti, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Nerve sparing; Phosphodiesterase type 5 inhibitors; Prostate cancer; Radical prostatectomy; Urinary continence recovery

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; ARTICLE; CONTINENCE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; FOLLOW UP; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PELVIS FLOOR; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATECTOMY; SPHINCTER; TREATMENT DURATION;

AGED; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SPARING TREATMENTS; PHOSPHODIESTERASE 5 INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; RECOVERY OF FUNCTION; URINARY INCONTINENCE; URINARY TRACT;

EID: 84875813307     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03149.x     Document Type: Article

References (33)

1. Heidenreich A, Bellmunt J, Bolla M etal. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 2011; 59: 61-71.
2. Sanda MG, Dunn RL, Michalski J etal. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 2008; 358: 1250-1261.
3. Shao YH, Demissie K, Shih W etal. Contemporary risk profile of prostate cancer in the United States. J. Natl. Cancer Inst. 2009; 101: 1280-1283.
4. Dubbelman YD, Dohle GR, Schroder FH. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur. Urol. 2006; 50: 711-718; discussion 718-20.
5. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008; 101: 1279-1283.
6. Montorsi F, Brock G, Lee J etal. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur. Urol. 2008; 54: 924-931.
7. Waldkirch ES, Uckert S, Langnase K etal. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur. Urol. 2007; 52: 495-501.
8. Fibbi B, Morelli A, Vignozzi L etal. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J. Sex. Med. 2010; 7 (1 Pt 1): 59-69.
9. Filippi S, Morelli A, Sandner P etal. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
10. Morelli A, Sarchielli E, Comeglio P etal. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J. Sex. Med. 2011; 8: 2746-2760.
11. Martinez-Salamanca JI, Carballido J, Eardley I etal. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur. Urol. 2011; 60: 527-535.
12. Gacci M, Ierardi A, Rose AD etal. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J. Sex. Med. 2010; 7 (1 Pt 1): 234-243.
13. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351.
14. Homma Y, Kawabe K, Tsukamoto T etal. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 261-266.
15. Centemero A, Rigatti L, Giraudo D etal. Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study. Eur. Urol. 2010; 57: 1039-1043.
16. Box GN, Ahlering TE. Robotic radical prostatectomy: long-term outcomes. Curr. Opin. Urol. 2008; 18: 173-179.
17. Touijer K, Eastham JA, Secin FP etal. Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J. Urol. 2008; 179: 1811-1817.
18. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3, 477 consecutive radical retropubic prostatectomies. J. Urol. 2004; 172 (6 Pt 1): 2227-2231.
19. Stanford JL, Feng Z, Hamilton AS etal. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354-360.
20. Gandaglia G, Suardi N, Gallina A etal. Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. J. Urol. 2012; 187: 569-574.
21. Wille S, Heidenreich A, Hofmann R, Engelmann U. Preoperative erectile function is one predictor for post prostatectomy incontinence. Neurourol. Urodyn. 2007; 26: 140-143.
22. Gacci M, Lapini A, Serni S etal. Predictors of quality of life after radical treatment for prostate cancer. Urol. Int. 2008; 80: 231-236.
23. Goode PS, Burgio KL, Johnson TM II etal. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA 2011; 305: 151-159.
24. Ribeiro LH, Prota C, Gomes CM etal. Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. J. Urol. 2010; 184: 1034-1039.
25. Abdollah F, Sun M, Suardi N etal. Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. Eur. Urol. 2012; 62: 42-52.
26. John H, Suter S, Hauri D. Effect of radical prostatectomy on urethral blood flow. Urology 2002; 59: 566-569.
27. Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J. Urol. 2010; 183: 629-633.
28. Gacci M, Corona G, Salvi M etal. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 2012; 61: 994-1003.
29. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int. J. Androl. 2009; 32: 587-598.
30. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J. Endocrinol. Invest. 2011; 34: 557-567.
31. Morelli A, Filippi S, Sandner P etal. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J. Sex. Med. 2009; 6: 1594-1608.
32. Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front. Horm. Res. 2009; 37: 108-122.
33. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med. Care 1998; 36: 1002-1012.